HIGHLIGHTS
- who: Martine Clozel from the Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland have published the article: Aprocitentan and the endothelin system in resistant hypertension, in the Journal: (JOURNAL)
- what: The efficacy of aprocitentan in both models of hypertension is consistent with the work showing that inducible overexpression of human ET-1 The aim is to demonstrate the bloodpressure-lowering effect of aprocitentan added to the stan- Can.
- how: This Article discusses the research that underpinned the discovery of this ERA and the choice of its first clinical indication patients with forms of hypertension that cannot . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.